| |
著者: E A Williams, J Stimpson, D Wang, S Plummer, I Garaiova, M E Barker, B M Corfe
雑誌名: Aliment Pharmacol Ther. 2009 Jan;29(1):97-103. doi: 10.1111/j.1365-2036.2008.03848.x. Epub 2008 Sep 9.
Abstract/Text
BACKGROUND: The efficacy of probiotics in alleviating the symptoms of irritable bowel syndrome (IBS) appears to be both strain- and dose-related.
AIM: To investigate the effect of LAB4, a multistrain probiotic preparation on symptoms of IBS. This probiotic preparation has not previously been assessed in IBS.
METHODS: Fifty-two participants with IBS, as defined by the Rome II criteria, participated in this double blind, randomized, placebo-controlled study. Participants were randomized to receive either a probiotic preparation comprising two strains of Lactobacillus acidophilus CUL60 (NCIMB 30157) and CUL21 (NCIMB 30156), Bifidobacterium lactis CUL34 (NCIMB 30172) and Bifidobacterium bifidum CUL20 (NCIMB 30153) at a total of 2.5 × 10(10) cfu/capsule or a placebo for 8 weeks. Participants reported their IBS symptoms using a questionnaire fortnightly during the intervention and at 2 weeks post-intervention.
RESULTS: A significantly greater improvement in the Symptom Severity Score of IBS and in scores for quality of life, days with pain and satisfaction with bowel habit was observed over the 8-week intervention period in the volunteers receiving the probiotic preparation than in the placebo group.
CONCLUSION: LAB4 multistrain probiotic supplement may benefit subjects with IBS.
© 2008 The Authors. Journal compilation © 2008 Blackwell Publishing Ltd.
PMID 18785988 Aliment Pharmacol Ther. 2009 Jan;29(1):97-103. doi: 10.1111/j.1365-2036.2008.03848.x. Epub 2008 Sep 9.
|
